<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01969214</url>
  </required_header>
  <id_info>
    <org_study_id>INQ/015213</org_study_id>
    <nct_id>NCT01969214</nct_id>
  </id_info>
  <brief_title>Safety and Efficacy of IQP-MM-101 in Reducing Symptoms of Diarrhoea</brief_title>
  <official_title>Open Label Study to Assess the Safety and Efficacy of IQP-MM-101 in Reducing Symptoms of Diarrhoea</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>InQpharm Group</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>InQpharm Group</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      Diosmectite in IQP-MM-101 has been used for diarrhoea control. Backed by data from several
      studies demonstrating their efficacy, the investigators are conducting this study to look
      into the efficacy and safety of IQP-MM-101 in diarrhoea control.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      The clinical study was intended to evaluate the safety and the potential reduction of
      diarrhoea recovery time post 1st intake of IQP-MM-101 in an open label, single arm,
      multicentre study over a 72 hours period. There were 2 clinic visits: the screening visit and
      final visit.

      At baseline visit (visit 1), written informed consents were collected. Each patients were
      given a diary and the following data were collected: demographics, vital signs, physical
      examination results, use of concomitant medication, previous medical history, and case
      history of the acute diarrhoea episode including date of first watery stool, number of stools
      over the past 24 hours, and presence of other associated symptoms over the past 24 hours
      (nausea, vomiting, abdominal pain).

      Subjects recorded the following data in the diary: date and hour of bowel movement, stool
      consistency (Bristol stool scale) presence of symptoms such as nausea, vomiting, abdominal
      pain and study IP consumption (number, date, and time of tablets taken) and time of vomiting
      (if any) each day during the treatment period. Additionally, subjects recorded the time
      absent from work and a subjective evaluation of their &quot;energy for everyday life&quot;.

      Visit 2 took place after 72 hours treatment period. Following data was collected:

        -  Vital signs, physical examination

        -  Adverse events

        -  Use of concomitant medication

        -  Compliance (returned IP and diary)

        -  Global evaluation of efficacy and safety by subjects and investigators

      During the 72-hour treatment period, all subjects were instructed to consumed IQP-MM-101
      according to the following dosage: one (1) tablet, three (3) times a day dissolved in at
      least 125mL (half a glass) of water.
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>October 2013</start_date>
  <completion_date type="Actual">July 2014</completion_date>
  <primary_completion_date type="Actual">June 2014</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>N/A</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Time (in Hours) Between the 1st Intake of IQP-MM-101 and First Formed or Hard Stool (Type 6 to 1) Followed by a Non Watery Stool (Type 6 to 1)</measure>
    <time_frame>96 hours</time_frame>
    <description>In essence the definition of recovery would be two consecutive non-watery stool (type 6 to 1) when stool before 1st intake of IQP-MM-101 is primarily watery (type 7).</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Time (Hours) From the First Intake to the Last Watery Stool</measure>
    <time_frame>96 hours</time_frame>
    <description>The last watery stool was assumed as the first-non watery stool</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of Daily Defecation</measure>
    <time_frame>96 hours</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of Watery Stools</measure>
    <time_frame>96 hours</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Stool Frequency</measure>
    <time_frame>96 hours</time_frame>
    <description>The mean number of daily defecation.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Percentage of Patients Having Recovered Within a Certain Time Period (Defined as Having Achieved the Primary Efficacy Endpoint)</measure>
    <time_frame>72 hours</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Abdominal Pain</measure>
    <time_frame>96 hours</time_frame>
    <description>Subjects feeling of abdominal pain was measured on visual analog scale of 0 - 100mm (no pain to severe pain).</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Time Off From Work</measure>
    <time_frame>1 week</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Evaluation of Subjects' Energy Level</measure>
    <time_frame>96 hours</time_frame>
    <description>The subjective measure of subjects' daily energy level was determined by severity of weakness felt by the subjects, measured on visual analog scale (0-100mm, 100mm being most severe weakness).</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Global Evaluation of Safety and Efficacy by Subjects and Investigators</measure>
    <time_frame>96 hours</time_frame>
    <description>The subjects and investigators will evaluate independently the safety of the investigational device (global scaled evaluation with &quot;very good&quot;, &quot;good&quot;, &quot;moderate&quot; and &quot;poor&quot;).</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Occurrence of Adverse Events (AEs)</measure>
    <time_frame>96 hours</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Associated Symptoms Such as Vomiting</measure>
    <time_frame>96 hours</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Stool Consistency</measure>
    <time_frame>96 hours</time_frame>
    <description>Stool consistency is measured by Bristol Stool Form Scale 1-7.
Separate hard lumps, like nuts (hard to pass)
Sausage-shaped, but lumpy
Like a sausage but with cracks on its surface
Like a sausage or snake, smooth and soft
Soft blobs with clear cut edges (easy to pass)
Fluffy pieces with ragged edges, a mushy stool
Watery, no solid pieces, entirely liquid Stool consistency is the mean of the scale measured each day.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Severity of Nausea</measure>
    <time_frame>96 hours</time_frame>
    <description>Subjects feeling of nausea was measured on visual analog scale of 0 - 100mm (no nausea to severe nausea).</description>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Actual">101</enrollment>
  <condition>Diarrhoea</condition>
  <arm_group>
    <arm_group_label>IQP-MM-101</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Dissolve the effervescent tablets in half a glass of water,to be taken orally
1 tablet, 3 times a day</description>
  </arm_group>
  <intervention>
    <intervention_type>Device</intervention_type>
    <intervention_name>IQP-MM-101</intervention_name>
    <description>Dissolve the effervescent tablets in half a glass of water, to be taken orally
1 tablet, 3 times a day</description>
    <arm_group_label>IQP-MM-101</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Age 18 to 65 years

          -  Good general health

          -  Acute diarrhoea episode defined as at least three watery stools per 24 hours over a
             period of 48 hours or less

          -  Acute diarrhoea of presumed infectious origin

          -  Patients with usually normal bowel movements (defecations) before onset of diarrhoea,
             that is, at least three normal stools per week and three or less normal stools per day

          -  Negative pregnancy test (ß HCG-test) for women with child bearing potential

          -  Written informed consent is a prerequisite for subject enrollment

        Exclusion Criteria:

          -  Known sensitivity to the ingredients of the device

          -  Fever &gt;38,5◦C

          -  Blood or pus in stools

          -  Dehydration requiring intravenous rehydration

          -  History of chronic diarrhoea (three or more loose or watery stools per day for at
             least 12 weeks, consecutive or not, in the preceding 12 months)

          -  Use of antidiarrhoeal agents over the month prior to baseline

          -  Diarrhoea possibly induced by antibiotics, laxative agents, thyroid hormones, or
             colchicine

          -  Irritable bowel syndrome

          -  Any other acute or chronic disease that could interfere with the evaluation of study
             device

          -  Females who are pregnant or lactating

          -  Subjects who have participated in another clinical trial in the 30 days before
             treatment period

          -  Inability to comply

          -  Presence of other factor(s) that, in the investigator's judgement, should preclude
             subject participation
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>65 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Ralf Uebelhack</last_name>
    <role>Principal Investigator</role>
    <affiliation>analyze &amp; realize GmbH</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>analyze &amp; realize GmbH</name>
      <address>
        <city>Berlin</city>
        <zip>10369</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Germany</country>
  </location_countries>
  <verification_date>January 2018</verification_date>
  <study_first_submitted>October 6, 2013</study_first_submitted>
  <study_first_submitted_qc>October 21, 2013</study_first_submitted_qc>
  <study_first_posted type="Estimate">October 25, 2013</study_first_posted>
  <results_first_submitted>January 4, 2016</results_first_submitted>
  <results_first_submitted_qc>February 20, 2020</results_first_submitted_qc>
  <results_first_posted type="Actual">March 4, 2020</results_first_posted>
  <last_update_submitted>February 20, 2020</last_update_submitted>
  <last_update_submitted_qc>February 20, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">March 4, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Diarrhea</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>

  <clinical_results>

    <participant_flow>
      <group_list>
        <group group_id="P1">
          <title>IQP-MM-101</title>
          <description>Dissolve the effervescent tablets in half a glass of water,to be taken orally
1 tablet, 3 times a day
IQP-MM-101: Dissolve the effervescent tablets in half a glass of water, to be taken orally
1 tablet, 3 times a day</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="101"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="86"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="15"/>
              </participants_list>
            </milestone>
          </milestone_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <population>Full analysis set (FAS) population consisted of all subjects who received at least one dose of investigational product (intent to treat). In cases where all dispensed investigational product is returned, the subject was considered non-treated and therefore was not included in the FAS.</population>
      <group_list>
        <group group_id="B1">
          <title>IQP-MM-101</title>
          <description>Dissolve the effervescent tablets in half a glass of water,to be taken orally
1 tablet, 3 times a day
IQP-MM-101: Dissolve the effervescent tablets in half a glass of water, to be taken orally
1 tablet, 3 times a day</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="86"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>years</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="35.1" spread="11.4"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Age</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>&lt;=18 years</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Between 18 and 65 years</title>
                  <measurement_list>
                    <measurement group_id="B1" value="86"/>
                  </measurement_list>
                </category>
                <category>
                  <title>&gt;=65 years</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Sex: Female, Male</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>Female</title>
                  <measurement_list>
                    <measurement group_id="B1" value="40"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Male</title>
                  <measurement_list>
                    <measurement group_id="B1" value="46"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Region of Enrollment</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>Germany</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="86"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Time (in Hours) Between the 1st Intake of IQP-MM-101 and First Formed or Hard Stool (Type 6 to 1) Followed by a Non Watery Stool (Type 6 to 1)</title>
        <description>In essence the definition of recovery would be two consecutive non-watery stool (type 6 to 1) when stool before 1st intake of IQP-MM-101 is primarily watery (type 7).</description>
        <time_frame>96 hours</time_frame>
        <population>6 participants recovered before first intake of IQP-MM-101, while in another, there was no defecation reported.</population>
        <group_list>
          <group group_id="O1">
            <title>IQP-MM-101</title>
            <description>Dissolve the effervescent tablets in half a glass of water,to be taken orally
1 tablet, 3 times a day
IQP-MM-101: Dissolve the effervescent tablets in half a glass of water, to be taken orally
1 tablet, 3 times a day</description>
          </group>
        </group_list>
        <measure>
          <title>Time (in Hours) Between the 1st Intake of IQP-MM-101 and First Formed or Hard Stool (Type 6 to 1) Followed by a Non Watery Stool (Type 6 to 1)</title>
          <description>In essence the definition of recovery would be two consecutive non-watery stool (type 6 to 1) when stool before 1st intake of IQP-MM-101 is primarily watery (type 7).</description>
          <population>6 participants recovered before first intake of IQP-MM-101, while in another, there was no defecation reported.</population>
          <units>hours</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="79"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="21.30" spread="16.02"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Time (Hours) From the First Intake to the Last Watery Stool</title>
        <description>The last watery stool was assumed as the first-non watery stool</description>
        <time_frame>96 hours</time_frame>
        <group_list>
          <group group_id="O1">
            <title>IQP-MM-101</title>
            <description>Dissolve the effervescent tablets in half a glass of water,to be taken orally
1 tablet, 3 times a day
IQP-MM-101: Dissolve the effervescent tablets in half a glass of water, to be taken orally
1 tablet, 3 times a day</description>
          </group>
        </group_list>
        <measure>
          <title>Time (Hours) From the First Intake to the Last Watery Stool</title>
          <description>The last watery stool was assumed as the first-non watery stool</description>
          <units>Hours</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="79"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="18.17" spread="15.85"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Number of Daily Defecation</title>
        <time_frame>96 hours</time_frame>
        <group_list>
          <group group_id="O1">
            <title>IQP-MM-101</title>
            <description>Dissolve the effervescent tablets in half a glass of water,to be taken orally
1 tablet, 3 times a day
IQP-MM-101: Dissolve the effervescent tablets in half a glass of water, to be taken orally
1 tablet, 3 times a day</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Daily Defecation</title>
          <units>stools</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="86"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Day 1</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="387"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Day 2</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="278"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Day 3</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="200"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Day 4</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="82"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Number of Watery Stools</title>
        <time_frame>96 hours</time_frame>
        <group_list>
          <group group_id="O1">
            <title>IQP-MM-101</title>
            <description>Dissolve the effervescent tablets in half a glass of water,to be taken orally
1 tablet, 3 times a day
IQP-MM-101: Dissolve the effervescent tablets in half a glass of water, to be taken orally
1 tablet, 3 times a day</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Watery Stools</title>
          <units>stools</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="86"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Day 1</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="292"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Day 2</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="72"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Day 3</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="20"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Day 4</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="10"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Stool Frequency</title>
        <description>The mean number of daily defecation.</description>
        <time_frame>96 hours</time_frame>
        <group_list>
          <group group_id="O1">
            <title>IQP-MM-101</title>
            <description>Dissolve the effervescent tablets in half a glass of water,to be taken orally
1 tablet, 3 times a day
IQP-MM-101: Dissolve the effervescent tablets in half a glass of water, to be taken orally
1 tablet, 3 times a day</description>
          </group>
        </group_list>
        <measure>
          <title>Stool Frequency</title>
          <description>The mean number of daily defecation.</description>
          <units>No. of daily defecation</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="86"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Stool Frequency Day 1</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="4.50" spread="2.57"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Stool Frequency Day 2</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="3.23" spread="1.90"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Stool Frequency Day 3</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2.33" spread="1.58"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Stool Frequency Day 4</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.95" spread="1.03"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Percentage of Patients Having Recovered Within a Certain Time Period (Defined as Having Achieved the Primary Efficacy Endpoint)</title>
        <time_frame>72 hours</time_frame>
        <group_list>
          <group group_id="O1">
            <title>IQP-MM-101</title>
            <description>Dissolve the effervescent tablets in half a glass of water,to be taken orally
1 tablet, 3 times a day
IQP-MM-101: Dissolve the effervescent tablets in half a glass of water, to be taken orally
1 tablet, 3 times a day</description>
          </group>
        </group_list>
        <measure>
          <title>Percentage of Patients Having Recovered Within a Certain Time Period (Defined as Having Achieved the Primary Efficacy Endpoint)</title>
          <units>Percentage of subjects</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="79"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Recovery time: Up to 24 hours</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="25.3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Recovery time: More than 24 up to 30 hours</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="21.5"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Recovery time: More than 30 up to 36 hours</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="8.9"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Recovery time: More than 36 up to 42 hours</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="7.6"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Recovery time: More than 42 up to 48 hours</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="16.5"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Recovery time: More than 48 up to 60 hours</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="10.1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Recovery time: More than 60 up to 72 hours</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="8.9"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Recovery time: More than 72 hours</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Abdominal Pain</title>
        <description>Subjects feeling of abdominal pain was measured on visual analog scale of 0 - 100mm (no pain to severe pain).</description>
        <time_frame>96 hours</time_frame>
        <population>All 86 subjects recorded abdominal pain on day 1 and day 2. 85 subjects recorded abdominal pain on day 3 and 67 subjects recorded abdominal pain on day 4.</population>
        <group_list>
          <group group_id="O1">
            <title>IQP-MM-101</title>
            <description>Dissolve the effervescent tablets in half a glass of water,to be taken orally
1 tablet, 3 times a day
IQP-MM-101: Dissolve the effervescent tablets in half a glass of water, to be taken orally
1 tablet, 3 times a day</description>
          </group>
        </group_list>
        <measure>
          <title>Abdominal Pain</title>
          <description>Subjects feeling of abdominal pain was measured on visual analog scale of 0 - 100mm (no pain to severe pain).</description>
          <population>All 86 subjects recorded abdominal pain on day 1 and day 2. 85 subjects recorded abdominal pain on day 3 and 67 subjects recorded abdominal pain on day 4.</population>
          <units>mm</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="86"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Severity of abdominal pain Day 1</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="86"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="56.2" spread="23.6"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Severity of abdominal pain Day 2</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="86"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="35.3" spread="20.8"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Severity of abdominal pain Day 3</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="85"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="18.7" spread="16.7"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Severity of abdominal pain Day 4</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="67"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="11.1" spread="14.3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Time Off From Work</title>
        <time_frame>1 week</time_frame>
        <group_list>
          <group group_id="O1">
            <title>IQP-MM-101</title>
            <description>Dissolve the effervescent tablets in half a glass of water,to be taken orally
1 tablet, 3 times a day
IQP-MM-101: Dissolve the effervescent tablets in half a glass of water, to be taken orally
1 tablet, 3 times a day</description>
          </group>
        </group_list>
        <measure>
          <title>Time Off From Work</title>
          <units>Percentage of subjects</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="86"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>0 day of absent</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="31.4"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>1 day of absent</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="4.7"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>2 days of absent</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="11.6"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>3 days of absent</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="7.0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>4 days of absent</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="12.8"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>5 days of absent</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="24.4"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>More than 6 days of absent</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="8.1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Evaluation of Subjects' Energy Level</title>
        <description>The subjective measure of subjects' daily energy level was determined by severity of weakness felt by the subjects, measured on visual analog scale (0-100mm, 100mm being most severe weakness).</description>
        <time_frame>96 hours</time_frame>
        <population>Only 85 subjects responded to Day 3 and only 67 subjects responded to Day 4 assessment of weakness</population>
        <group_list>
          <group group_id="O1">
            <title>IQP-MM-101</title>
            <description>Dissolve the effervescent tablets in half a glass of water,to be taken orally
1 tablet, 3 times a day
IQP-MM-101: Dissolve the effervescent tablets in half a glass of water, to be taken orally
1 tablet, 3 times a day</description>
          </group>
        </group_list>
        <measure>
          <title>Evaluation of Subjects' Energy Level</title>
          <description>The subjective measure of subjects' daily energy level was determined by severity of weakness felt by the subjects, measured on visual analog scale (0-100mm, 100mm being most severe weakness).</description>
          <population>Only 85 subjects responded to Day 3 and only 67 subjects responded to Day 4 assessment of weakness</population>
          <units>mm</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="86"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Severity of Weakness Day 1</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="86"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="67.5" spread="21.5"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Severity of Weakness Day 2</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="86"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="45.7" spread="24.7"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Severity of Weakness Day 3</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="85"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="29.5" spread="24.6"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Severity of Weakness Day 4</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="67"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="16.8" spread="19.7"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Global Evaluation of Safety and Efficacy by Subjects and Investigators</title>
        <description>The subjects and investigators will evaluate independently the safety of the investigational device (global scaled evaluation with &quot;very good&quot;, &quot;good&quot;, &quot;moderate&quot; and &quot;poor&quot;).</description>
        <time_frame>96 hours</time_frame>
        <group_list>
          <group group_id="O1">
            <title>IQP-MM-101</title>
            <description>Dissolve the effervescent tablets in half a glass of water,to be taken orally
1 tablet, 3 times a day
IQP-MM-101: Dissolve the effervescent tablets in half a glass of water, to be taken orally
1 tablet, 3 times a day</description>
          </group>
        </group_list>
        <measure>
          <title>Global Evaluation of Safety and Efficacy by Subjects and Investigators</title>
          <description>The subjects and investigators will evaluate independently the safety of the investigational device (global scaled evaluation with &quot;very good&quot;, &quot;good&quot;, &quot;moderate&quot; and &quot;poor&quot;).</description>
          <units>participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="86"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Efficacy by Investigator - Very Good</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="21"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Efficacy by Investigator - Good</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="61"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Efficacy by Investigator - Moderate</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Efficacy by Investigator - Poor</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Efficacy by Subjects - Very Good</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="28"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Efficacy by Subjects - Good</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="54"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Efficacy by Subjects - Moderate</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Efficacy by Subjects - Poor</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Safety by Investigator - Very Good</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="51"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Safety by Investigator - Good</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="34"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Safety by Investigator - Moderate</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Safety by Investigator - Poor</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Safety by Subjects - Very Good</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="50"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Safety by Subjects - Good</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="36"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Safety by Subjects - Moderate</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Safety by Subjects - Poor</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Occurrence of Adverse Events (AEs)</title>
        <time_frame>96 hours</time_frame>
        <group_list>
          <group group_id="O1">
            <title>IQP-MM-101</title>
            <description>Dissolve the effervescent tablets in half a glass of water,to be taken orally
1 tablet, 3 times a day
IQP-MM-101: Dissolve the effervescent tablets in half a glass of water, to be taken orally
1 tablet, 3 times a day</description>
          </group>
        </group_list>
        <measure>
          <title>Occurrence of Adverse Events (AEs)</title>
          <units>Adverse Events</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="99"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="7"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Associated Symptoms Such as Vomiting</title>
        <time_frame>96 hours</time_frame>
        <group_list>
          <group group_id="O1">
            <title>IQP-MM-101</title>
            <description>Dissolve the effervescent tablets in half a glass of water,to be taken orally
1 tablet, 3 times a day
IQP-MM-101: Dissolve the effervescent tablets in half a glass of water, to be taken orally
1 tablet, 3 times a day</description>
          </group>
        </group_list>
        <measure>
          <title>Associated Symptoms Such as Vomiting</title>
          <units>Percentage of subjects</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="86"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Affected subjects at day 1</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="23.3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Affected subjects at day 2</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="3.5"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Affected subjects at day 3</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="3.5"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Affected subjects at day 4</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="3.5"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Stool Consistency</title>
        <description>Stool consistency is measured by Bristol Stool Form Scale 1-7.
Separate hard lumps, like nuts (hard to pass)
Sausage-shaped, but lumpy
Like a sausage but with cracks on its surface
Like a sausage or snake, smooth and soft
Soft blobs with clear cut edges (easy to pass)
Fluffy pieces with ragged edges, a mushy stool
Watery, no solid pieces, entirely liquid Stool consistency is the mean of the scale measured each day.</description>
        <time_frame>96 hours</time_frame>
        <population>387, 278, 200 and 82 stool samples were obtained on day 1, 2, 3 and 4 respectively.</population>
        <group_list>
          <group group_id="O1">
            <title>IQP-MM-101</title>
            <description>Dissolve the effervescent tablets in half a glass of water,to be taken orally
1 tablet, 3 times a day
IQP-MM-101: Dissolve the effervescent tablets in half a glass of water, to be taken orally
1 tablet, 3 times a day</description>
          </group>
        </group_list>
        <measure>
          <title>Stool Consistency</title>
          <description>Stool consistency is measured by Bristol Stool Form Scale 1-7.
Separate hard lumps, like nuts (hard to pass)
Sausage-shaped, but lumpy
Like a sausage but with cracks on its surface
Like a sausage or snake, smooth and soft
Soft blobs with clear cut edges (easy to pass)
Fluffy pieces with ragged edges, a mushy stool
Watery, no solid pieces, entirely liquid Stool consistency is the mean of the scale measured each day.</description>
          <population>387, 278, 200 and 82 stool samples were obtained on day 1, 2, 3 and 4 respectively.</population>
          <units>score on a scale</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <units_analyzed>stool samples</units_analyzed>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="86"/>
              </count_list>
            </analyzed>
            <analyzed>
              <units>stool samples</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="387"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Type of Stool Day 1</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="86"/>
                  </count_list>
                </analyzed>
                <analyzed>
                  <units>stool samples</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="387"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="6.66" spread="0.84"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Type of Stool Day 2</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="86"/>
                  </count_list>
                </analyzed>
                <analyzed>
                  <units>stool samples</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="278"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="5.83" spread="1.33"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Type of Stool Day 3</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="86"/>
                  </count_list>
                </analyzed>
                <analyzed>
                  <units>stool samples</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="200"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="4.18" spread="1.50"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Type of Stool Day 4</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="86"/>
                  </count_list>
                </analyzed>
                <analyzed>
                  <units>stool samples</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="82"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="3.32" spread="1.25"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Severity of Nausea</title>
        <description>Subjects feeling of nausea was measured on visual analog scale of 0 - 100mm (no nausea to severe nausea).</description>
        <time_frame>96 hours</time_frame>
        <population>All 86 subjects recorded nausea on day 1 and day 2. 85 subjects recorded nausea on day 3 and 67 subjects recorded nausea on day 4.</population>
        <group_list>
          <group group_id="O1">
            <title>IQP-MM-101</title>
            <description>Dissolve the effervescent tablets in half a glass of water,to be taken orally
1 tablet, 3 times a day
IQP-MM-101: Dissolve the effervescent tablets in half a glass of water, to be taken orally
1 tablet, 3 times a day</description>
          </group>
        </group_list>
        <measure>
          <title>Severity of Nausea</title>
          <description>Subjects feeling of nausea was measured on visual analog scale of 0 - 100mm (no nausea to severe nausea).</description>
          <population>All 86 subjects recorded nausea on day 1 and day 2. 85 subjects recorded nausea on day 3 and 67 subjects recorded nausea on day 4.</population>
          <units>mm</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="86"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Severity of nausea Day 1</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="86"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="44.8" spread="29.5"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Severity of nausea Day 2</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="86"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="28.1" spread="23.4"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Severity of nausea Day 3</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="85"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="12.9" spread="16.0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Severity of nausea Day 4</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="67"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="8.3" spread="13.7"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
    </outcome_list>

    <reported_events>
      <time_frame>72 hours</time_frame>
      <group_list>
        <group group_id="E1">
          <title>IQP-MM-101</title>
          <description>Dissolve the effervescent tablets in half a glass of water,to be taken orally
1 tablet, 3 times a day
IQP-MM-101: Dissolve the effervescent tablets in half a glass of water, to be taken orally
1 tablet, 3 times a day</description>
        </group>
      </group_list>
      <serious_events>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="99"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>0</frequency_threshold>
        <default_assessment>Non-systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="6" subjects_at_risk="99"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>General disorders</title>
            <event_list>
              <event>
                <sub_title>Cold</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="99"/>
              </event>
              <event>
                <sub_title>Cough</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="99"/>
              </event>
              <event>
                <sub_title>Headache</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="99"/>
              </event>
              <event>
                <sub_title>Heartburn</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="99"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Infections and infestations</title>
            <event_list>
              <event>
                <sub_title>Tinea Corporis</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="99"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Respiratory, thoracic and mediastinal disorders</title>
            <event_list>
              <event>
                <sub_title>Viral Infection of the Pharynx</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="99"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>Principal Investigators are NOT employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>There is NOT an agreement between Principal Investigators and the Sponsor (or its agents) that restricts the PI's rights to discuss or publish trial results after the trial is completed. </restrictive_agreement>
    </certain_agreements>
    <point_of_contact>
      <name_or_title>Felix Alt</name_or_title>
      <organization>Analyze &amp; Realize</organization>
      <phone>+49 30 4000 8194</phone>
      <email>FAlt@a-r.com</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

